两融数据显示，该股最新融资余额为72.39亿元，近5日增加282.01万元，增幅为0.04%。（数据宝） 12月19日药明康德大宗交易一览 药明康德12月19日大宗交易平台共发生10笔成交，合计成交量300.00万股，成交金额2.64亿元。成交价 格均为87.85元，相对今日收盘价折价5.00%。从参与大宗交易营业部来看，机构专用席位共出现在5笔 成交的买方或卖方营业部中，合计成交金额为2.00亿元，净买入2.00亿元。 进一步统计，近3个月内该股累计发生42笔大宗交易，合计成交金额为16.91亿元。 证券时报·数据宝统计显示，药明康德今日收盘价为92.47元，上涨2.08%，日换手率为1.88%，成交额为 43.16亿元，全天主力资金净流入4.02亿元，近5日该股累计下跌1.68%，近5日资金合计净流入1.25亿 元。 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 78.96 | ...

Group 1 - The core viewpoint of the article highlights a general increase in the pharmaceutical outsourcing sector, with notable stock price rises for companies such as WuXi Biologics (6.11%), Kelun Pharmaceutical (5.52%), and others [1] - According to a report from Century Securities, the recent NDAA legislation has led to a reduction in geopolitical risks, positively impacting the industry [1] - In the first three quarters, the total amount of license-out agreements for innovative drugs in China reached a historical high, indicating a continuous improvement in the innovation drug sector [1] Group 2 - The CXO sector is experiencing a recovery in performance and new orders, with market attention shifting towards preclinical safety evaluation assets [1] - The CXO industry, as an upstream segment of the innovative drug supply chain, is expected to benefit from the enhanced competitiveness of domestic innovative drugs, leading to a rebound in industry prosperity [1] - The outlook for CXO is positive, with expectations for both performance and valuation recovery following a complete industry cycle [1]

Group 1 - The pharmaceutical outsourcing sector is experiencing a general increase, with notable stock price rises for companies such as WuXi Biologics (6.11%), Kelun Pharmaceutical (5.52%), and others [1] - A recent report from Century Securities indicates that the NDAA bill has been implemented, leading to a reduction in geopolitical risks [1] - In the first three quarters, the total amount of license-out agreements for innovative drugs in China reached a historical high, indicating a continuous improvement in the innovative drug industry [1] Group 2 - The performance and new orders for CXO companies are showing signs of improvement, with the market beginning to focus on preclinical safety evaluation assets [1] - CXO companies, as part of the upstream of the innovative drug industry chain, are expected to benefit from the enhanced competitiveness of domestic innovative drugs, leading to a recovery in industry prosperity [1] - The industry is anticipated to see a dual recovery in both performance and valuation for CXO companies [1]

Investment Overview - The company, WuXi AppTec Healthcare Holding S.C.S.p, has signed a Subscription Agreement to invest €10 million (approximately ¥82.76 million) in the Jeito II S.L.P. private equity fund, representing 1.07% of the fund's total raised shares [2][4] - After the completion of the Subscription Agreement and Transfer Agreement, WuXi Lux Holding will hold a total of €30 million in A-class shares, accounting for approximately 3.22% of the total raised fund [3][8] - This investment does not require approval from the company's board of directors or shareholders and does not constitute a related party transaction or a major asset restructuring as defined by regulations [2][3] Fund Management and Structure - The investment fund is established under French law, targeting innovative companies in the biopharmaceutical sector with significant clinical needs and commercialization potential [8][15] - The fund's total size is capped at €1.2 billion, with approximately €931 million raised to date [8] - The fund's management team, Jeito Capital S.A.S., is noted for its professional investment management capabilities and compliance with local laws [4][6] Investment Strategy and Goals - The fund aims to invest in 14 to 17 early-stage medical innovation startups, focusing on biopharmaceutical companies [15][16] - The expected return model is based on asset appreciation after deducting management fees [16] - The fund will enter a liquidation phase at the end of its term, with a structured process for asset realization and distribution to investors [17] Impact on the Company - The investment is expected to enhance the company's understanding of developments in the European biopharmaceutical sector, which is a key potential customer base [19] - The company believes that the management team's experience and resources will provide critical growth capital and operational guidance to European biopharmaceutical startups [19] - The investment will not significantly impact the company's financial status or operational results, as it is made with the company's own funds while ensuring sufficient capital for daily operations [19]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月19日，药明康德收涨2.08%，收盘价为92.47元，发生10笔大宗交易，合计成交量300万股，成交金 额2.64亿元。 第1笔成交价格为87.85元，成交78.96万股，成交金额6,936.74万元，溢价率为-5.00%，买方营业部为机 构专用，卖方营业部为华泰证券股份有限公司上海分公司。 第6笔成交价格为87.85元，成交19.95万股，成交金额1,752.63万元，溢价率为-5.00%，买方营业部为瑞 银证券有限责任公司上海花园石桥路证券营业部，卖方营业部为华泰证券股份有限公司上海分公司。 第7笔成交价格为87.85元，成交16.49万股，成交金额1,448.31万元，溢价率为-5.00%，买方营业部为瑞 银证券有限责任公司上海花园石桥路证券营业部，卖方营业部为华泰证券股份有限公司上海分公司。 第8笔成交价格为87.85元，成交6.23万股，成交金额547.49万元，溢价率为-5.00%，买方营业部为瑞银 证券有限责任公司上海花园石桥路证券营业部，卖方营业部为华泰证券股份有限公司上海分公司。 第9笔成交价格为87.85元，成 ...

中国经济网北京12月19日讯 药明康德(603259.SH)昨日晚间发布关于股东权益变动触及1%刻度的提 示性公告。 2025年11月26日至2025年12月17日，药明康德加权均价为91.477元。经计算，上述股东减持金额合 计约26.99亿元。 (责任编辑：田云绯) 2025年12月17日，公司收到信息披露义务人发出的通知，获知其于2025年11月26日至2025年12月17 日通过集中竞价和大宗交易方式合计减持公司股份29,508,754股，占公告日公司总股本的0.989%。信息 披露义务人及与实际控制人签署投票委托书的股东合计持有公司股份数从535,711,396股减少至 506,202,642股，持股比例从17.95%减少至16.97%，权益变动触及1%刻度。 公司实际控制人为Ge Li（李革）、张朝晖、刘晓钟。信息披露义务人G&C IV Hong Kong Limited、G&C V Limited、G&C VI Limited、G&C VII Limited、嘉兴厚锦投资合伙企业（有限合伙）、 嘉兴厚毅投资合伙企业（有限合伙）、嘉兴厚毓投资合伙企业（有限合伙）、嘉兴厚咨投资合伙企业 （有限合伙） ...

Core Viewpoint - The healthcare sector in mainland China has experienced a pullback due to the results of national medical insurance drug price negotiations and subsequent profit-taking, but the fundamentals remain unchanged, presenting a good entry opportunity for 2026 [1] Group 1: Industry Outlook - The trend of innovative drug licensing is expected to continue, with multiple potential targets and drug forms anticipated to bring new licensing opportunities next year [1] - Key global Phase III clinical data readings for these licensed assets will be crucial for market sentiment and warrant close attention [1] - Geopolitical concerns regarding China's pharmaceutical R&D outsourcing industry (CXO) have peaked, and a stable medical policy environment in China is expected to continue supporting innovation [1] Group 2: Market Recovery - A more moderate drug procurement policy is expected to drive a recovery in the medical device and diagnostics sectors [1] Group 3: Stock Preferences - The company prefers biotechnology and CXO stocks, with top picks including Innovent Biologics (01801), Kelun-Biotech (06990), WuXi AppTec H-shares (02359), WuXi AppTec A-shares (603259.SH), and WuXi Biologics (02268) [1] - The target price for Innovent Biologics has been slightly raised from HKD 110 to HKD 111, maintaining a "Buy" rating, while the target price for WuXi Biologics has increased from HKD 74 to HKD 82, also with a "Buy" rating [1]

Core Viewpoint - The report from JPMorgan indicates that despite a recent downturn in the mainland healthcare sector due to national medical insurance drug price negotiations and subsequent profit-taking, the fundamental outlook for the industry remains unchanged, presenting a good entry opportunity for 2026 [1] Group 1: Industry Outlook - The healthcare sector experienced a decline in September and October, but JPMorgan believes this weakness provides a favorable entry point for investors looking towards 2026 [1] - The trend of innovative drug licensing is expected to continue, with multiple potential targets and drug forms anticipated to bring new licensing opportunities in the coming year [1] - Geopolitical concerns regarding China's pharmaceutical research outsourcing industry (CXO) are believed to have peaked, and a stable medical policy environment is expected to support innovation [1] Group 2: Market Recovery - A more moderate approach to drug volume procurement is expected to drive a recovery in the medical device and diagnostics sectors [1] Group 3: Stock Preferences - JPMorgan favors biotechnology and CXO stocks, specifically highlighting Innovent Biologics, Kelun-Biotech, WuXi AppTec H-shares, WuXi AppTec A-shares, and WuXi Biologics as preferred picks [1] - The target price for Innovent Biologics has been slightly raised from HKD 110 to HKD 111, while WuXi Biologics' target price has increased from HKD 74 to HKD 82, with both stocks rated as "Overweight" [1]

Company News - GuoDun Quantum's chairman, Lv Pin, unexpectedly passed away [7] - CICC announced a cash dividend of 434 million yuan for the first half of 2025, with the record date set for December 26 [8] - Haitian Flavoring announced that its cash dividend ratio will not be less than 80% annually for the next three years (2025-2027) [9] - Sichuan Road and Bridge announced that China Post Insurance has increased its stake to 5% [10] - Zhongwei Company announced plans to acquire Hangzhou Zhonggui's equity, leading to a stock suspension [11] - WuXi AppTec reported that 18 shareholders, including the third, fourth, and sixth largest, collectively reduced their holdings by 29.5 million shares between November 26 and December 17 [11] - Lida Xin announced that shareholder Li Chunhua reduced his stake by 1.56% between December 10 and December 17 [12] - Visionox plans to sign an investment cooperation agreement to advance the Hefei 8.6-generation AMOLED production line project, with a second-phase capital of 9.443 billion yuan [12] - Western Mining announced that its wholly-owned subsidiary, Geermu West Mining Resources, has obtained a mining license, with gold reserves of 2.86 tons [13] - Yidong Electronics announced that a related party reduced its holdings by 2.3463 million shares between December 10 and December 17 [14] - Shandong Highway plans to provision for a long-term equity investment impairment of approximately 690 million yuan in Dongxing Securities [15] - GuoAo Technology's former actual controller, Chen Chongjun, was sentenced to six years in prison for manipulating the securities market, with a fine of 4 million yuan [16] Industry News - The Hong Kong Stock Exchange is consulting market opinions on optimizing the framework for trading units, with potential adjustments affecting about 25% of issuers [5] - The Ministry of Commerce responded to the latest developments in export controls on rare earth-related items, indicating that some Chinese exporters have met the basic requirements for applying for general licenses [5] - The National Digital Exchange System Engineering Technology Research Center, in collaboration with China Mobile and China Unicom, has achieved breakthroughs in resource scheduling efficiency and reliability through a "multi-modal on-the-fly computing" model [5] - The scale of China's biomanufacturing industry has continued to grow, reaching a total scale of 1.1 trillion yuan, with biopharmaceutical product output accounting for over 70% of the global total [5] - Platinum has become a highly sought-after asset, with the price of pure platinum reaching 815 yuan per gram, and futures contracts seeing a significant increase of 5.32% on December 18 [6]

Industry News - The State Council issued opinions on cracking down on illegal tobacco activities, emphasizing strict regulation of e-cigarettes and severe penalties for illegal production, wholesale, transportation, and sales [2][7] - Wu Qing attended a meeting to discuss the capital market's 14th Five-Year Plan, focusing on risk prevention, strong regulation, and promoting high-quality development [6][7] - The Ministry of Commerce responded to the European Commission's investigations into Chinese companies, highlighting the discriminatory nature of these actions and affirming China's commitment to protecting its enterprises [2][7] Company News - GuoDun Quantum's chairman, Lv Pin, unexpectedly passed away [10] - China International Capital Corporation announced a cash dividend of 434 million yuan for the first half of 2025, with the record date set for December 26 [10] - Li Chunhua, a shareholder of Lida Xin, reduced his stake by 1.56% between December 10 and December 17 [10] - Visionox plans to sign an investment cooperation agreement to advance the Hefei 8.6-generation AMOLED production line project, with a capital requirement of 9.443 billion yuan [10] Investment Opportunities - Micron Technology reported a booming demand for High Bandwidth Memory (HBM), with a projected compound annual growth rate (CAGR) of approximately 40%, increasing from about $35 billion in 2025 to around $100 billion by 2028 [20] - The persistent demand for memory in AI computing highlights the critical role of HBM, as the need for memory capacity and bandwidth continues to grow significantly [20]